retatrutide trial results The experimental GLP-1 drug 'reta' also improved blood sugar and heart health metrics. But side effects led more than 1 in 10 to drop out of trials early: https://bit.ly/4x6Aexb retatrutide phase 2 trial results

These medications effectively slow gastric emptying, which has raised concerns regarding the risk of residual gastric volume (RGV) and potential pulmonary aspiration during procedures requiring sedation

Recent study results shared at the Endocrine Society meeting ENDO 2026 indicate that semaglutide was linked to higher weight loss and a 15% decrease in broken bones when it was compared to other weight loss medications

Wayne Winegarden, Director, PRI Center for Medical Economics and Innovation, said: GLP-1s are among the most promising medical breakthroughs in decades But allowing unauthorised manufacturers to mass market GLP-1 knockoffs outside FDA safeguards creates significant patient safety risks and undermines trust in the healthcare system. Safety and innovation concerns The report cites concerns including poor storage, dosing errors, questionable ingredient sourcing and counterfeit products

This makes it useful beyond just skin it may modulate systemic inflammation

About half of adults who have taken GLP-1s say it was difficult to afford the cost of these drugs

Recovery and Muscle Growth Optimizing recovery and muscle growth are key goals in both athletic and clinical research